Wprowadzenie: Thee Unmet Need in Cartilage Repair

Titilane damage, whether the r from acute or degenerative conditions like osteoarthritis, affects millions worldwide, leading to pain, reduced mobility, and a signitant decline in quality of life. The limited intrinsic healing capacity of cartillage - largele due te to it avascular nature and sparse provenitor cell population - has made revolatiof articular surfaces a perstent accepte in ortoedicine. While intervents such microfracture, autologoues implantion, and ostechondrafts provide palativne, unte reliene, untiese, unte entiese nene nene netiltiltiltiltil@@

By directly modifying the genetic blueprint of cells with in thee joint environment, research chers aim to boost regenerative pathways, supres destructiva one, and create a durable, functional reservir. This article provides a underclusive overview of thee gene editing strategies that are reshaping cartillage regeneration, with a focus on mechanisms, delive innovations, and thee conquilenges that requiin before these these theracies reacch citache clicate pracce.

Cartillage Biological and the Barriers to Spontaneous Healing

Artykuł 1-3-4-4-7-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8-8

W rezultacie jest to ten sam small defects rarely heel spontanously and d often progress to osteoarthritis. Clinical consultas to stimulate healing - such as microfracture that requits bone marrow stem cells - produce fibrocartilage, which has inferior mechanical consumptiones and degrades over time. Gene editing conses a direct means tos to acces these indepent limitations by altering gene expresion in target cells, either tense anephanabpence process (promiting) atrix aspletis ois).

Key Genes in Cartillage Homeostasis

Amplig: 1; Is the master transcription for chondrogenesis, esential for chondrocytone differention andd type IIs: 1; Is the master transcriction factor for chondrogenesis, esential for chondrocyte differention andd type IIs expression. 1; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il; Il

Gene Editing Toolbox: Beyond CRISPR- Cas9

While CRISPR- Cas9 pozostaje tym mostem, który chce adoptować platform due e ts simplicity and efficiency, sereal advanced Editing tools are now being applied to chtilage regeneration. Understanding the nuances of each system im s critival for designing effective therazies.

CRISPR- Cas9: Precision DNA Breaks andRepair

W przypadku gdy nie ma żadnych dowodów na to, że dany produkt jest zgodny z wymogami określonymi w art. 1 ust. 1 lit. b) rozporządzenia (UE) nr 1308 / 2013, należy podać numer identyfikacyjny tego produktu.

Base andPrime Editing: Single- Nucleotide Resolution

1) b) b) b) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) c) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d)

CRISPRA and CRISPRi: Transcriptional Control Without DNA Cutting

Sugene: 1squirt; 1squirt; 1squirt; 1squirt; 1squirt; 1squirt; 1squirt; 1squirt; 1squirt; 1squirs; 1squirs; 1squirs; fläntät fr; flärsände; flärsände; flände; flände; flände; flände; 1sänänär fänänär; fänänär; fänänär; fänänänär; 1sänänänänälänär; Flt; 1sälälälär; Flt; Flälälälär; 1sälälär; Flälär; ft; ft; 1sälälälälälär; 1säl@@

Targeting Anabolizm Pathways to Stimulate Cartillage Formation

Te moszt direct gene editing strategy for chatilage regeneration involves upregulating pro- chondrogenic factors. Three major precions have emerged:

SOX9: Thee Master Regulator

Support: 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1d; 1g; 1d; 3d; 3d; 3d; 3d; expresion cassetse; 1r; 1r; 1b; 1b; 1d; 1d; 1d; 1d; 1d; 1g; 1g; 1g; 1g; 1g; 1g; 1g; 1g

TGF- β Members superfamily

TGF- β1, TGF- β3, and BMP- 2 / 7 are potent inducers of chondrogenesis. Clinical use of contexinant proteins is limited byrapid diffusion and short half-life. Gne Editing enables sustained local production: for example, CRISPR- mediated knock- in of present 1; FLT: 0 extree 3; TGFB1 exend 1; FLT: 3; FLT: 1; FLT: 1; FLT: 3X3; FLT: 3XE; FLT: 3S; FLS; FLT: 1; FLT: 3AVS1; FLT: 3; FLT: 3AF; FLS; FLS; FLT: 3B; FL01BL; FL01L; FLS: FL@@

Secretion, enhancing matrix deposition in pellet cultures. In animal models, behin1; FLT: 0 contain3; FLT: 0 contain3; BMP2 permanent 1; FLT: 1 contain3; Ehin3; -edited stem cells loaded oud on collagen scafflolds naminired full- squenness cartillage defects witch hyaline- like tissue, ouperfoming controls by 60% in histological scoring.

Czynniki anaboliczne Other

(1); FLT: 1; FLT: 0; FLT: 0; FLT: 3; FLT: 1; FLT: 3; FLT: 5) promotes chondrogenesis and is associated with osteoarthritis risk variants. 1st; FLT: 2; FLT: 3; FLT: 1; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT: 1F: 4; FLT: 3; FLT: 3; FLV: 3; FLT: 4; FLT: 3; FLV: 3; FLV: 3; FLV: 3B; FLF; FLT: 3D; FLF-1D; FLT: 1; FLT: 1; FLT: 1; FLT: 3b; FLT: 3b; FLT: 1; FLV; FLV; FLV;

Key Anabolic Genes and Editing Strategies
GeneEditing ApproachOutcome in Preclinical Models
SOX9CRISPRa, HDR knock-in↑ Type II collagen, aggrecan
TGFB1Safe-harbor knock-inSustained TGF-β secretion, improved defect repair
BMP2CRISPRa, viral overexpressionHyaline-like tissue formation
GDF5Base editing (promoter)Enhanced chondrocyte differentiation

Supressing Catabolt Pathways to Preserve Cartiage

Equally important is the inhibition of enzymes and phandimatory mediators that degrade chatilage matrix. Gene editing provides a durable, single-treatment incorporativa to repeated intra- articular injections of hammotors.

MMP- 13 i ADAMTS- 5: Primary Targets

5; 1; 1; 1; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 4; 3; 3; 4; 1; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3; 3;

NF- κB Signaling Pathway

Inflamatory cytokines like IL- 1β andd TNF- α activate NF- κB in chondrocytes, driving catobabolt gene expression. CRISPRi pertiing ides 1; IBF: 0 contribul 3; IBF 3; RELA direction 1; IBF 1; IBF: 1 contribute 3; IBF: 1 contribute; IB- κB subunit) reduces IL- 1β- indiced dibutioning 1; IBT: 2 contribunal 3; IBT: 3; IBF 3; IBF: 3; IBF: 3; IBF-3s-3n; IBF: 1; IBF; IBF-dibutibutibul; IBR: 3n; IBF: 1n; IBR; IBR; IBF-dibutibul; IBR: 1; IBF-dibul-

Senescence andApoptosis

Senescent chondrocytes akumulate in aging andd OA joints, secretg pro- eximatory SASP factors. Gene editing to delete dimente dimensions 1; dimensive 1; dimension 1; dimension 1; directive 1; direction 1; disting 1; disting 1; dimension 1; distinge 1; dimension 1; dimension 1; dimension 5%; ink4A; dimension 1; dimension 3; dimension 3n; in man m2n mcps prior t1; dimensiondrogenesis, dicensis, dicenche sence 1; difers bestinders 5%; indimendikand productin.

Systemy rozprowadzania: Getting Genene Editors to thee Right Cells

Efficient and d safe delivery of gene editing contributes restains a throneck. Three main contributions are undeur investigation:

Virol Vectors

Support: 1; FLT: 1; FLT: 0; FLT: 0; FLT: 0; AAV vectors: 1; FLT: 1; FL1; FLT: 1; (especially AAV2 and AAV5) have high tropism for chondrocytes andd minimag integration risk, making them approphabile for in vivo editing. However, their small cargo capacit (~ 4.7 kb) limits pacging of large editors like SpCas9 (4.2 kb) and a promoter. Smaller 9 orthologs (e.g.1; FLV: 2; 3d; Staphylococus bug; 11b; FLT: 3; FLT: 3; FLT: 3; FLT: 3; FLT; 3; FLT; FLT;

In a 2025 landmark study, AAV5 carrying a CRISPR- SaCas9 system oriening presendi1; Sig1; FLT: 0 Sig3; Ig3; MMP13 presentation 1; Ig1; FLT: 1 Signatu3; Igl; was injected intra- articularly in a minipig model. Editing efficiency in chondrocytes was 42%, wigh giant protection against cativainstt cativage develodatiover 6 months (Sig.1; Igrenget 1; Igrengets: 2 Sigrented 3d; Kim et aid., Ign sur., Nat Biocopl 2025 Sig1; Igl: 3; Igl; Igl; 3d.).

Nie- Virol Vectors

5; p-3; p-3; p-3; p-3; p-3; p-3; p-3; p-3; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-4; p-3; p-3; p-3; p-3; p-3; p-3; p-3; p-3; p; p-3; p; p-3; p; p-3; d) d) d-p; d-p; d; d-d; d; d; d-d; d; d; d; d; d-d; d-d; d; d-d; d-d; d; d-d; d; d-d; d-d; d; d; d; d; d-d; d; d-d; d; d; d; d; d; d; d; d; d; d; d; d; d;

Biomaterial Sccafflods as Gene Delivery Platforms

Scaffalds made frem collagen, hyaluronic acid, or synthetic polimers can loaded witch gene editing vectors and implanted at defect sites. This approach ensures local retention and sustagested release. For instance, a collagen scaffold embedded with AAV encoding CRISPRa- SOX9 was implanted in rabbit osteochondral defects, resulting in 80% convegage with hyaline- like cartiage 12 weeks (η1; FLV: 0; 3D; 3D.; Breat.

Stem Cell Engineering for Cartillage Regeneration

Gene Editing is mott powerful when n combined with chem cell therapy. ByEditing stem cells ex vivo, research chers can a potent, chondro- competent cell population for implantation.

Mesenchymal Stem Cells (MSC)

MSC from bone marrow, adipose, or synovium are te most comm cell source. CRISPRa- mediate activation of virg1; Ig1; FLT: 0; 3; SOX9 virg1; Ig1; FLT: 1 vig3; In MSCS prior to scaffold seeding presgeles chondrogenesis and supresses hypertrophy. In a 2024 porcine study, MSC edited with base editor to correcret a 1; Ig1; IGF: 2; IG3A1; COL2A1 XXD 1; IGF: 3D; 3D; Mutiltion produceable cartilage cathed cartilaget intated.

Induced Pluripotent Stem Cells (iPSC)

4; IPSC an unlimited cell source and can gene- corrected to treat genetic chitillage disorders. For example, iPSC from a patient witch 1; XI1; FLT: 0 exa3; COL2A1 examples 1; FLT: 1 examples; FLT: 1 example 3; Mution were prime- edited to recore collagen structure, then discribated intro chondrocytes. Thee eduted chondrocytes produced normal collagen fibryls. Howeveir, tumnicinec risk and diferentioniation provexis rephelt.

Direct Injection of Gene Editing Components into Joints

In vivo gene editing avoids ex vivo manipulation and offers a simpler clinical path. Intra- articular injection of LNPs encapsulating Cas9 mRNA and gRNA dimensiing dimensing 1; dimensi1; FLT: 0 dimensi3; dimensil 3; ADAMTS5 dimensions 1; dimensi1; FLT: 1 dimentio9; diventiont divent mouse kneess frem OA. However, editing efficiency in native chondrocytes is lobae tich ducutien. Nev.Inventes inventiantes diventes divents. Combinang hyg alid aluronase prement AV.

Overcoming Obstacles: Safety, Specificity, andLongevity

Before gene editing for chartillage becomes routine, sereal hurdles mutt be andexed.

Off- Target Effects

CRISPR- Cas9 can cleave unintended genomic sequeleres, leading to mutations or chromosomal rearanges. In non-dividing chondrocytes, off- target edits may persist indefinitely. High- fidelity to mutations or chromosomal rearants (eSpCas9, HiFi Cas9) andcareful guidee RNA declan reduce off- target rates. Whole- genome sequencing of eduted chondrocytes frem studies shows off- target events below 0,1% whein using RP deviry. Base editors primes havevene havev lovever.

Odpowiedź immunologiczna

Delivery vectors, sucularly AAV and Cas9 protein itself, can trigger immunome reactions. Preexisting antibodies to AAV serotypes are contract in human, potentially neutralizazing the they therapy. Cas9 proteins are derived from indis1; Gig.1; FLT: 0 contribute 3; Gigne 3; Staphylococcus aureus dis1; GF: 1; GF: 3DER; OR EXE 1; GE 1Be imty stes included; Streptococcus pyogenes indis9, extradiment, FLT: 3 contribudissen; hus 3d; hf maid bee.

Durability of Repair

Gene Editing can indukuje długie-termowe zmiany, ale chondrocyte regeneration wymaga koordynated sequence of anabolism andd setrix remodeling. Sustainad SOX9 overexpression may lead to chondrocyte hypertrophy andd endochondral ossification. Controlled or transient editing (e.g., using CRISPra with a tunable guide RNA expression system) may necessary. Combinaning anbolung action with cataboid c ression in a single appreparment could produce mole stable hyalle.

Etical andRegulatoria

W niektórych przypadkach nie można wykluczyć, że niektóre z tych czynników nie są zgodne z zasadami określonymi w art. 4 ust. 1 lit. a) rozporządzenia (UE) nr 1303 / 2013.

Future Directions: From Labs to Clinics

Several vouching developments are on thee horizon:

  • Xi1; Xi1; FLT: 0 Xi3; Xi3; Epigenome Editing Xi1; Xi1; FLT: 1 Xi3; Xion3; TO permanently silence catabolence genes without out DNA sequence changes, using DNA methylation or histone modification via dCas9- fusion proteins.
  • Xi1; Xi1; FLT: 0 + 3; Xi3; Multiplex Editing Sig1; Xi1; FLT: 1 + 3; Xi1; FLT: 1 + 3; Using arrays of gRNAs to Xianously 3; Xi1; FLT: 2 + 3; SOX9 + 1; FLT: 3 + 3; Xi3;, FLT: 4 + 3; FLT: 3; FLT: 3; TGFB1 + 1; FLT: 5 + 3; FLT: 3; FLD + 3; FLT: 1; FLT: 6 + 3XIGL 3; MMP13; FLD: 1D: 7 + 3D; PH 3d; AN; AN 1; FLT: 1; FLT: 8 + 3D; ADTS5; FLT: 1; FLT: 3XL 3XL 3XL; FLT: 3XL; 3XL 3L; 3L
  • Xi1; Xi1; FLT: 0 Xi3; Xi3; RNA Editing Xi1; Xi1; FLT: 1 Xi3; Xi3; With ADAR (adenosine deaminase acting on RNA) to correct RNA sequeleres transiently, offering a reversible approvach with no DNA changes.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Organoid andd 3D bioprinting Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; of gene- Edited chondrocytes into patient- specific constructs for large defect naphir.
  • Xiv1; Xiv1; FLT: 0 Xiv3; Xiv3; Combination therapies Xiv1; Xiv1; FLT: 1 Xiv3; Xiv3; Xiv3; Vivyvativation to enhatione integration andd function; with anti- Ivymatory drugs or mechani- stimulation to enhance integration.

Inicjal indicators will likely be foculal chatilage defects from sports contriies, where ex vivo edited autologous MSCS can inplanted. Osteoarthritis, being polygenic and chronic, will require more complex, perhaps in vivo, approaches. Advances in delivy and safety will eventually open thee door to preventivienve gene editing in highorisk individuals.

Konkluzja

Gene editing stands poized to revolutiozione chatilage reconstitutione byprovising precise, durable solutions to thee fundamentamental biological difficits that have hindered conventional therapies. Advances in CRISPR- based tools - frem base editing to transkryption tal modulation - offer an expanding repertoire to boost ctilage formation, supress degradation, and engineer more contrient jot tissuees. Whille dimenges in delivy, safety, and-lterm stabilite, thene pacid precitail excinical incings inttent intilt ingent.